Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6911509 | 0.82 | MALT1 (0.32) | LMNAALDH1A1SMN1; SMN2KMT2AMALT1 | |
| SCHEMBL6807241 | 0.80 | — | — | |
| SCHEMBL7566288 | 0.77 | CDK1 (0.45) | LMNAALDH1A1SMN1; SMN2KMT2AMALT1 | |
| SCHEMBL6804437 | 0.73 | HTR6 (0.55) | ALDH1A1SMN1; SMN2KMT2AMALT1MEN1 | |
| SCHEMBL6911507 | 0.70 | — | — | |
| SCHEMBL6802653 | 0.70 | MEN1 (0.40) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7562977 | 0.68 | CDK1 (0.43) | LMNAALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6800094 | 0.68 | — | — | |
| SCHEMBL7563531 | 0.64 | MCL1 (0.36) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6802957 | 0.62 | CCR4 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010142-A1 | Novel process | NOVO NORDISK A/S (DK) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010142-A1 | Novel process | UGT1A1, CYP4X1, CYP4B1 | LMNA 2517/4885ALDH1A1 146/4885SMN1; SMN2 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.